Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.
Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores
Luo Li, Pin Guo, De-Hong Wan and Guang-Ping Liu
Naphthalimides have potent anti-cancer activity against human cancer cells. UNBS5162, as a derivative of naphthalimide, is capable of removing primary amine group and reducing toxicity. Recently studies have discovered that UNBS5162 could significantly down-regulate pro-angiogenic chemokines in human prostate tissue, indicating it might have an anti-angiogenic effect. In this work, we intended to explore the functional role of UNBS5162 on glioma cells proliferation, migration and invasion. Cell viability, migration and invasion capabilities of U251 cells were examined by Cell Counting Kit-8 (CCK-8) and transwell assays. The cell apoptosis was tested by Annexin V-FITC/ PI and flow cytometry. Apoptosis-associated proteins and the related-markers of Phosphatidylinositol 3-kinase (PI3K) were examined by western blot analysis. The CCK-8 test suggested that UNBS5162 markedly suppressed the viability of glioma cell line U251. UNBS5162 markedly repressed glioma cell migration and invasion, which was shown from results of transwell assay. Further, UNBS5162 promoted glioma cell apoptosis rate, accompanied by reduced expression level of anti-apoptotic protein Bcl-2 and elevated expression level of pro-apoptotic protein Active Caspase-3 and Bax in U251 cell line administrated with UNBS5162. Additionally, UNBS5162 suppressed the Phosphatidylinositol 3-kinase (PI3K) signaling pathways in U251 cell line. Therefore, the current finding unveils that UNBS5162 can repress glioma cell viability and induce glioma cell apoptosis by regulating the PI3K signaling pathway, suggesting it might be a potentially promising drug target for clinical glioma therapy.